Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026

First-in-class anti-CD155 antibody demonstrated favorable safety profile and preliminary anti-tumor activity across multiple difficult-to-treat cancer types JERUSALEM, June 17, 2026 /PRNewswire/ -- Nectin Therapeutics, a clinical-stage oncology company developing first-in-class...